The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
An article from
Dive Brief
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Published June 18, 2026
Jacob Bell/BioPharma Dive
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Adaptive Biotechn
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's…
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering…
